HER3 expression was... significantly associated with decreased disease-specific survival HER2 cellular signaling is affected by the expression of other type 1 growth factor receptor family members ...

In preclinical experiments, seribantumab prevented the activation of HER3 signaling in cells that harbor an NRG1 gene fusion. In addition to extensive nonclinical characterization and testing ...

effectively and synergistically inhibits EGFR/HER3 downstream signaling, leading to further inhibition of tumor growth. Its lead compound demonstrated favorable stability and a PK profile ...

Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody-drug conjugate (ADC) in clinical trials for lung cancer. The designation ...

A mid-stage trial of Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan has hit the mark and will form the basis of regulatory filings for the drug later this year.

From April 25 to 30, 2025, the American Association for Cancer Research (AACR) Annual Meeting will take place in Chicago. CStone will showcase its latest preclinical studies on five internally ...